TMPO

Lamina-associated polypeptide 2, isoforms beta/gamma · P42167 · TMPO on Sugi Atlas →

0 patent compounds predicted against TMPO, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TMPO by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Vorinostat in Children PHASE1/PHASE2COMPLETED
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS PHASE1/PHASE2WITHDRAWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy PHASE2COMPLETED
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor PHASE2RECRUITING
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors PHASE1WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
miRNA-452 in Patients With Preeclampsia and Its Correlation With MMP-9 nanCOMPLETED
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 nanCOMPLETED
Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study nanUNKNOWN
Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum nanCOMPLETED
Molecular Profile of the Evolution of Inclusion Body Myositis nanCOMPLETED
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TMPO binder may also engage these)

ProteinNameSimilarity
Q61029 1.000 Q61029 →
Q62733 1.000 Q62733 →
Q5REG6 0.987 Q5REG6 →
Q5TYQ8 0.986 Q5TYQ8 →
Q4KLH6 0.986 Q4KLH6 →
Q8N3X1 0.985 Q8N3X1 →
Q6ZQ06 0.985 Q6ZQ06 →
Q96D71 0.985 Q96D71 →
Q9ULJ8 0.985 Q9ULJ8 →
Q6ZQ03 0.984 Q6ZQ03 →
Q96T21 0.984 Q96T21 →
Q13625 0.984 Q13625 →
Q9ERH4 0.984 Q9ERH4 →
E7F568 0.984 E7F568 →
Q6PJT7 0.984 Q6PJT7 →
Q8BJ05 0.984 Q8BJ05 →
Q9Z136 0.984 Q9Z136 →
Q9Y2H5 0.983 Q9Y2H5 →
Q503U3 0.983 Q503U3 →
Q5XIN3 0.983 Q5XIN3 →
Q08AZ1 0.983 Q08AZ1 →
Q4R6F6 0.983 Q4R6F6 →
Q5VUA4 0.983 Q5VUA4 →
Q8NDI1 0.983 Q8NDI1 →
Q9WU62 0.983 Q9WU62 →
Q2MJV9 0.983 Q2MJV9 →
Q7ZXV6 0.983 Q7ZXV6 →
Q8CG79 0.983 Q8CG79 →
Q9CYA6 0.983 Q9CYA6 →
D3ZUI5 0.983 D3ZUI5 →